Baptiste Louveau
Overview
Explore the profile of Baptiste Louveau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Louveau B, Resche-Rigon M, Lesimple T, Meda L, Pracht M, Baroudjian B, et al.
Clin Cancer Res
. 2021 May;
27(14):3876-3883.
PMID: 33947696
Purpose: In metastatic melanoma, cyclin D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. In this phase I-II study,...
22.
Guissart C, Mouzat K, Kantar J, Louveau B, Vilquin P, Polge A, et al.
Sci Rep
. 2020 Nov;
10(1):20738.
PMID: 33244158
Amyotrophic lateral sclerosis (ALS) is the most common and severe adult-onset motoneuron disease and has currently no effective therapy. Approximately 20% of familial ALS cases are caused by dominantly-inherited mutations...
23.
Louveau B, Jouenne F, Tetu P, Sadoux A, Gruber A, Lopes E, et al.
Target Oncol
. 2020 Nov;
15(6):759-771.
PMID: 33151472
Background: Tumor molecular deciphering is crucial in clinical management. Pan-cancer next-generation sequencing panels have moved towards exhaustive molecular characterization. However, because of treatment resistance and the growing emergence of pharmacological...
24.
Jouenne F, Sadoux A, Lorillon G, Louveau B, Bugnet E, Meignin V, et al.
J Clin Pathol
. 2020 Sep;
74(8):533-536.
PMID: 32873703
Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplastic disease driven by activating mutations in the mitogen-activating protein kinase signalling pathway, including the mutation and deletions (del). Next-generation sequencing...
25.
Louveau B, Jouenne F, Kaguelidou F, Landras A, Goldwirt L, Mourah S
Therapie
. 2020 Mar;
75(2):183-193.
PMID: 32173061
The therapeutic management of cancers has undergone considerable changes due to the emergence of genomics tools and tumor molecular deciphering. In this context, a dual pharmacological approach based on pharmacogenomic...
26.
Reger De Moura C, Vercellino L, Jouenne F, Baroudjian B, Sadoux A, Louveau B, et al.
Transl Oncol
. 2019 Dec;
13(2):275-286.
PMID: 31874374
The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response...
27.
Mourah S, Louveau B, Dumaz N
Curr Opin Oncol
. 2019 Dec;
32(2):91-97.
PMID: 31833956
Purpose Of Review: Thanks to mitogen-activated protein kinase inhibitors (MAPKi) and immune checkpoint inhibitors (ICI), major progress has been made in the field of melanoma treatment. However, long-term success is...
28.
Courbette O, Aupiais C, Viala J, Hugot J, Roblin X, Candon S, et al.
J Pediatr Gastroenterol Nutr
. 2019 Oct;
70(3):310-317.
PMID: 31651668
Objective: Infliximab (IFX) is a frequent therapeutic option for Crohn disease (CD) patients. Early detection of responders to IFX is critical for the management of CD in order to avoid...
29.
Louveau B, Jouenne F, Reger De Moura C, Sadoux A, Baroudjian B, Delyon J, et al.
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31426590
In metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers....
30.
Courbette O, Aupiais C, Viala J, Hugot J, Louveau B, Chatenoud L, et al.
J Pediatr Gastroenterol Nutr
. 2019 Mar;
69(2):189-193.
PMID: 30921262
Objectives: In adult inflammatory bowel disease (IBD) treated by anti-TNF antibodies, paradoxical psoriasis has an estimated prevalence of 1.6 to 22%, especially in infliximab (IFX)-treated patients. Little is known in...